Price T Rowe Associates Inc Akero Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

$867 Billion
Q4 2024

A detailed history of Price T Rowe Associates Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,321,972 shares of AKRO stock, worth $218 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,321,972

Previous 3,808,359 13.49%

Holding current value

$218 Million

Previous $109 Million 10.05%

% of portfolio

0.01%

Previous 0.01%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$26.75 - $35.28 $13.7 Million - $18.1 Million	513,613 Added 13.49%	4,321,972 $120 Million
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $7.25 Million - $9.92 Million	-337,992 Reduced 8.15%	3,808,359 $109 Million
Q2 2024 Aug 14, 2024	BUY	$18.31 - $24.62 $1.57 Million - $2.11 Million	85,872 Added 2.11%	4,146,351 $97.3 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $6.83 Million - $12 Million	384,555 Added 10.46%	4,060,479 $103 Million
Q4 2023 Feb 14, 2024	SELL	$11.38 - $50.33 $1.53 Million - $6.76 Million	-134,270 Reduced 3.52%	3,675,924 $85.8 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $21.4 Million - $27.2 Million	520,551 Added 15.82%	3,810,194 $193 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $24.6 Million - $37.9 Million	665,963 Added 25.38%	3,289,643 $154 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $8.3 Million - $11.2 Million	222,643 Added 9.27%	2,623,680 $100 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $31.4 Million - $51.4 Million	938,613 Added 64.18%	2,401,037 $132 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $10.2 Million - $34.3 Million	1,007,122 Added 221.2%	1,462,424 $49.8 Million
Q2 2022 Aug 15, 2022	SELL	$8.0 - $15.01 $496 - $930	-62 Reduced 0.01%	455,302 $4.3 Million
Q1 2022 May 16, 2022	SELL	$12.97 - $22.26 $9.13 Million - $15.7 Million	-704,166 Reduced 60.73%	455,364 $6.46 Million
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $157,588 - $208,109	7,931 Added 0.69%	1,159,530 $24.5 Million
Q3 2021 Nov 15, 2021	SELL	$18.65 - $25.46 $48,564 - $66,297	-2,604 Reduced 0.23%	1,151,599 $25.7 Million
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $6.48 Million - $8.45 Million	261,057 Added 29.23%	1,154,203 $28.6 Million
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $5.67 Million - $8.06 Million	235,691 Added 35.85%	893,146 $25.9 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $16.5 Million - $19.7 Million	657,455 New	657,455 $17 Million

Others Institutions Holding AKRO

# of Institutions

209

Shares Held

74.3M

Call Options Held

321K

Put Options Held

558K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.35B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Akero Therapeutics, Inc. Transaction History